

BACKGROUND

Endocrine-gland-derived vascular endothelial growth factor, or EG-VEGF, is angiogenic growth factor specifically expressed in the ovaries, testis, adrenal and placental tissues. The identification of tissue-selective angiogenic factors raises the possibility that other secreted molecules in this class exist. EG-VEGF expression correlates with vascularity in polycystic ovary syndrome, a leading cause of infertility.

Recombinant human EG-VEGF is a non-glycosylated protein containing 86 amino acids and having a molecular mass of 9.6 kDa.

Alternative Names:

Prokineticin 1, PROK1

Amino Acid Sequence:

AVITGACERD VQCGAGTCCA ISLWLRGLRM CTPLGREGEE
CHPGSHKVPF FRKRKHTCP CLPNLLCSRF PDGRYRCSMD
LKNINF

TECHNICAL INFORMATION

Source: *E.coli*

Physical Appearance:

Sterile Filtered white lyophilized (freeze-dried) powder.

Formulation:

Recombinant human EG-VEGF is lyophilized with no additives

Stability:

Lyophilized product is very stable at -20°C. Reconstituted material should be aliquoted and frozen at -20°C. It is recommended that a carrier protein (0.1% HSA or BSA) is added for long term storage.

Reconstitution:

Centrifuge vial before opening. When reconstituting the product, gently pipet and wash down the sides of the vial to ensure full recovery of the protein into solution. It is recommended to reconstitute the lyophilized product with sterile water at a concentration of 0.1 mg/ml, which can be further diluted into other aqueous solutions.

Protein Content and Purity determined by:

- UV spectroscopy at 280 nm
- RP-HPLC calibrated against a known standard
- Quantitation against a known standard via reducing and non-reducing SDS-PAGE gels.

Endotoxin Level:

Endotoxin level, as measured by LAL analysis, is <0.01ng/ug or <0.1EU/ug.

Biological Activity:

The activity is determined by the dose-dependent proliferation of MIA PaCa-2 cells and is typically 1-4 ug/mL.

Products are for research use only. They are not intended for human, animal, or diagnostic applications.

